CTOs on the Move

Saluda Medical

www.saludamedical.com

 
Saluda Medical is a global medical device company focused on patient outcomes, science, and engineering to transform the neuromodulation industry with a platform of closed-loop technologies that optimize therapy by reading, recording, and responding to the nerves' response to stimulation` The company's first product, Evoke®, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system designed to treat chronic pain, a condition that affects more than 540 million people globally` SCS treats the condition by stimulating the spinal cord and altering the transmission of pain signals to the brain` Saluda's proprietary Evoke System is the only closed-loop SCS system designed ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Forest Laboratories

Forest Laboratories is a pharmaceutical company headquartered in New York City, US. The company's research and development spending has grown rapidly in recent years and as of 2007, approached almost a billion US dollars a year, which put it on the list of the top 100 global corporations in R&D spending. Forest Laboratories is also known for licensing European pharmaceuticals for sale in the United States.

Caldera Pharmaceuticals

Caldera Pharmaceuticals is a Los Alamos, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RTI Products

RTI Products is a Amesbury, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tiber Laboratories

Tiber Laboratories is a Suwanee, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UroGen

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.